WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 315239

CAS#: 226256-56-0 (free base)

Description: Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar in North America and Australia and as Mimpara in Europe. Cinacalcet is used to treat secondary hyperparathyroidism (elevated parathyroid hormone levels), a consequence of having end-stage renal disease. Cinacalcet is also indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma.

Chemical Structure

CAS# 226256-56-0 (free base)

Theoretical Analysis

MedKoo Cat#: 315239
Name: Cinacalcet
CAS#: 226256-56-0 (free base)
Chemical Formula: C22H22F3N
Exact Mass: 357.17043
Molecular Weight: 357.41
Elemental Analysis: C, 73.93; H, 6.20; F, 15.95; N, 3.92

Price and Availability

Size Price Availability Quantity
10.0mg USD 240.0 2 Weeks
50.0mg USD 700.0 2 Weeks
Bulk inquiry

Related CAS #: 364782-34-3 (HCl)   226256-56-0 (free base)    

Synonym: Sensipar. (R)N1(1naphthyl)ethyl33(trifluoromethyl)phenylpropan1amine

IUPAC/Chemical Name: (R)-N-(1-(naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine.


InChi Code: InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 357.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Fisher MM, Cabrera SM, Imel EA. Successful treatment of neonatal severe hyperparathyroidism with cinacalcet in two patients. Endocrinol Diabetes Metab Case Rep. 2015;2015:150040. doi: 10.1530/EDM-15-0040. Epub 2015 Jun 18. PubMed PMID: 26161261; PubMed Central PMCID: PMC4496565.

2: Sharma AK, Masterson R, Holt SG, Tan SJ, Hughes PD, Chu M, Jayadeva P, Toussaint ND. Impact of cinacalcet pre-transplantation on mineral metabolism in renal transplant recipients. Nephrology (Carlton). 2015 Jun 9. doi: 10.1111/nep.12536. [Epub ahead of print] PubMed PMID: 26072678.

3: Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9. PubMed PMID: 26059012.

4: Chang TI, Abdalla S, London GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Dehmel B, Goodman WG, Chertow GM. The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial. J Hum Hypertens. 2015 Jun 4. doi: 10.1038/jhh.2015.56. [Epub ahead of print] PubMed PMID: 26040438.

5: Mingione A, Verdelli C, Terranegra A, Soldati L, Corbetta S. Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors. Curr Cancer Drug Targets. 2015 Jun 2. [Epub ahead of print] PubMed PMID: 26033088.

6: Afsar B, Agca E, Turk S. Comparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitol. J Clin Pharmacol. 2015 Jun 1. doi: 10.1002/jcph.556. [Epub ahead of print] PubMed PMID: 26032009.

7: Hong YA, Cho YS, Kim SW, Jung MY, Lee EA, Ko GJ, Pyo HJ, Hwang SY, Suh S, Kwon YJ. Diameter of Parathyroid Glands Measured by Computed Tomography as a Predictive Indicator for Response to Cinacalcet in Dialysis Patients with Secondary Hyperparathyroidism. Kidney Blood Press Res. 2015;40(3):277-87. doi: 10.1159/000368503. Epub 2015 May 22. PubMed PMID: 26022985.

8: Gillespie IA, Floege J, Gioni I, Drüeke TB, de Francisco AL, Anker SD, Kubo Y, Wheeler DC, Froissart M; on behalf the ARO Steering Committee collaborators. Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortality. Pharmacoepidemiol Drug Saf. 2015 Jul;24(7):738-47. doi: 10.1002/pds.3789. Epub 2015 May 26. PubMed PMID: 26011775.

9: Tenhola S, Hendy GN, Valta H, Canaff L, Lee BS, Wong BY, Välimäki MJ, Cole DE, Mäkitie O. Cinacalcet Treatment in an Adolescent With Concurrent 22q11.2 Deletion Syndrome and Familial Hypocalciuric Hypercalcemia Type 3 Caused by AP2S1 Mutation. J Clin Endocrinol Metab. 2015 Jul;100(7):2515-8. doi: 10.1210/jc.2015-1518. Epub 2015 May 20. PubMed PMID: 25993639.

10: Lorenzoni V, Trieste L, Turchetti G. The cost-effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet. Expert Rev Pharmacoecon Outcomes Res. 2015 Aug;15(4):611-24. doi: 10.1586/14737167.2015.1047348. Epub 2015 May 17. PubMed PMID: 25988877.